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for 422 patients with schizophrenia was analysed according to how total and medication costs
differed across sites and which variables were likely to predict total or service-speciﬁc costs.
Method: Service use was recorded continuously during a 12-month follow-up. Prescribed
psychotropic medication was recorded at baseline and 12 months later. Service use data were
transformed into EURO, log-transformed and analysed using linear regression models.
Results: Although samples were homogeneous, large inter-site cost differences were found
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associated more with region or socio-demographic characteristics than with disorder related
parameters.
Conclusions: The ﬁndings conﬁrm remarkable differences in direct costs of patients with
schizophrenia across Europe. However, the relative stability of medication costs suggests a need
to analyse mechanisms that inﬂuence service-speciﬁc costs for schizophrenia.






Research on the costs of care for patients suffering from
schizophrenia has increased during recent years. However,
evidence is still scarce, as most studies target only selected
aspects of the wide range of treatments or services provided
for patients with schizophrenia. A considerable proportion
of research focuses on psychopharmacological treatment
regimes and their economic consequences. This was stimu-
lated by the need to evaluate whether or not the prescription
of costly second-generation neuroleptic drugs, which were
increasingly launched throughout the 1990s, is cost-effective
in routine care. However, many of these cost-effectiveness.de (H.J. Salize).
All rights reserved.studies preferred a decision model approach, feeding selected
administrative, epidemiological, or clinical data into decision
trees. The appropriateness of this approach is an issue of
recent controversial debate (Hansen et al., 2006; Beard et al.,
2006; Barbui and Lintas, 2006). Follow-up studies assessing
and analysing psychopharmacologic drug consumption and
the associated costs from a naturalistic perspective on a
patient level are still scarce. Rarer still are cross-country
comparisons that address total cost of care for patients
suffering from schizophrenia with a particular focus on
medication costs, as in this case, the diversity of international
community mental health care models has to be controlled
for. Such an approach multiplies the methodological pro-
blems. Among the factors to be considered are varying price
levels and funding mechanisms for mental health care, which
are even more complex than the various community care
concepts (Knapp et al., 2003; Windmeijer et al., 2006).
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for patients with schizophrenia across European countries are
available to date, e.g., the EPSILON study (Knapp et al., 2002),
that compared service utilization and cost proﬁles of people
with schizophrenia living in ﬁve European locations. The
study found higher needs, greater symptom severity and
longer psychiatric history being associated with higher
costs. However, most of cost studies in this ﬁeld often fail to
link costs to outcomes of care, and they do not necessarily
specify the cost of psychopharmacological drug use. In the
face of recent doubts about the cost-effectiveness of second-
generation antipsychotics informed by controversial ﬁndings
from various trials and meta-analyses (Rosenheck, 2006;
Rosenheck et al., 2006; Jones et al., 2006; Davies et al., 2008;
Zhu et al., 2008; Carpenter and Buchanan, 2008), quantitative
data in this ﬁeld are fundamental to the ongoing transforma-
tion of community care systems. To bridge this gap, we
analysed the total cost of care for patients with a diagnosis of
schizophrenia in six countries as a part of a randomised
controlled European trial, in which particular emphasis
was put on the prospective recording of the cost of psycho-
pharmacologic drug use on the patient level. The following
research questions were addressed:
• What are the overall costs and service-speciﬁc costs of care
for patients with schizophrenia in the six sites and how do
these differ across sites?
• What variables predict total and service-speciﬁc costs of
care across the sites?
2. Material and methods
2.1. Study
This randomised controlled trial was conducted in com-
munity psychiatric services in Granada (Spain), Groningen
(the Netherlands) London (UK), Lund (Sweden), Mannheim
(Germany) and Zurich (Switzerland), covering urban and
mixed urban–rural areas.
The original trial hypothesised that regular use of a novel
computer-mediated procedure (called DIALOG) in routine
meetings between clinicians and community patients with
schizophrenia would be associated with a more favourable
quality of life, fewerunmetneeds for care, andhigher treatment
satisfaction after a one-year period as opposed to treatment as
usual. ByapplyingDIALOG, clinicians discussed regularly eleven
life and treatment domains with the patients in the experi-
mental group and asked them to rate their satisfaction with
each domain. The rating was followed by a question as to
whether the patients wanted any additional or different help in
the given domain. The control group patients continued with
standard treatment. The study design, study sample, settings,
aims, and primary outcomes are described in detail elsewhere
(Priebe et al., 2002, 2007).
In order to analyse the costs of mental health care for
participating patients, the assessments included a detailed
prospective recording of mental health service use covering a
12-month follow-up period. Additionally, for each patient the
prescription of psychotropic medication (including type of
drug, brand name, daily dosage and dosage form) was
recorded at baseline and again 12 months later.The prime objective of the cost analyses (based on the
service use and medication data) was to determine and
analyse the total mental health care costs and service-speciﬁc
costs, including psychopharmacologic drug cost for patients
across all sites. In a second step, predictors of the cost of care
were analyzed.
2.2. Inclusion criteria
Clients who met the following inclusion criteria were
identiﬁed: living in the community (not 24-hour assisted
accommodation) and treated as outpatients by community
mental health teams; at least 3 months of continuous care
in the current service; capable of giving informed consent;
sufﬁcient knowledge of the language of the host country; a
primary diagnosis of schizophrenia or related psychotic
disorder (ICD-10=F20–F29); aged between 18 and 65 years
of age (to constrain the sample to the core group of com-
munity psychiatry and exclude patients suffering from co-
morbidity such as somatic diseases or dementia); meeting
with their keyworker at least once every twomonths,with the
expectation that they would continue with the service for the
next 12 months; and absence of severe organic psychiatric
illness or primary substance abuse. Written informed consent
was obtained from all patients participating in the study.
Pre-intervention data collection was from December 2002
to September 2004, and post-intervention data was collected
from December 2003 to May 2005. Patients were interviewed
at both time points by trained researchers (psychologists who
did not belong to the clinical teams that were responsible for
the treatment of patients), either at the relevant community
mental health service or at home. The interviews included the
whole set of scales and instruments as described below (see
assessments). The psychologists were not blinded whether
patients were in the experimental or control group.
2.2.1. Organisational characteristics of services involved
The population size of the involved catchment areas varied
(Granada: 188,000 inhabitants; Groningen: 400,000; London:
710,000; Lund: 100,000; Mannheim: 320,000; Zurich:
382,000). Although all included countries adopted commu-
nity mental health care as a basic concept for treating patients
with schizophrenia, theactual provision of inpatient, outpatient
or rehabilitative services differed considerably from region to
region, according to national characteristics of mental health
care delivery or other factors.
Granada, where 3 community mental health teams
(CMHT) with a total of 19 staff members were provided to
serve the patients with schizophrenia of the catchment area,
was the least well equipped region in terms of CMHTs,
psychiatric hospital beds (0.10–0.11 per 1000 population) or
places in sheltered accommodation (0.08 per 1000 popula-
tion). Groningen had 4 CMHTs with 55 staff members, a
psychiatric bed rate of ca. 0.4 per 1000 population and ca. 0.10
sheltered accommodation places per 1000 population. The
East London site, which collaborated in the study offered 267
psychiatric hospital beds (0.37 per 1000 population). Out-
patient care in Londonwas provided by 10 CMHTs with a total
of 400 staff members. In Lund, there were 4 CMHTs with 15–
18 staff members each. The psychiatric bed rate of the Lund
catchment area was 0.85 per 1000 population and places in
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Outpatient mental health care in Mannheim and Zurich
differed from the other centres, as in Germany and Switzer-
land, numerous private psychiatrists in ofﬁce practice (whose
treatments are covered by the Swiss or German health
insurance schemes and were not disproportionally more
expensive against those provided by outpatient departments)
are strongly involved in outpatient mental health care. In the
Zurich region alone, approx. 200 psychiatrists are based in
ofﬁce practice (ca. 0.5 per 1000 population). Compared to
other countries, this dense network of outpatient psychia-
trists diminishes the role of German or Swiss CMHTs to a
certain degree. On the other hand, rehabilitative and
residential care is a major sector of mental health care both
in Switzerland and Germany, where places in sheltered
accommodation mounted to 0.52 (Mannheim) and 1.05
(Zurich) per 1000 population. Mannheim had 0.52 psychiatric
hospital beds per 1000 population, whereas the rate in Zurich
was 0.78.
The average case-load of a CMHT-keyworker varied also. It
ranged from 8 (Zurich) 10–12 (Mannheim, London), to 18.5
(Groningen) and 25 (Lund). Case-loads in Granada were
probably much higher, but unfortunately case-load ﬁgures
from Granada were not available. Usually, CMHTs include
part- or full time psychiatric nurses or social workers.
Psychiatrists or psychologists are part of the teams in most,
but not in all countries (e.g. for reasons mentioned above, not
in Switzerland or Germany). Some teams add additional
professions e.g. occupational or other therapists, while others
do not provide such services. CMHTs usually are responsible
for health care planning and coordination, case management,
supportive counselling, the prescription or application of
psychotropic medication, psychotherapy, home visits or other
services. Again, this differs with the national mental health
care principles or concepts and the capacities of regional
services.
These capacities and rates must be seen as rough es-
timates, as inpatient or outpatient capacities of catchment
areas are rarely selective and tend to overlap with neigh-
bouring regions. Additionally a variety of additional rehabili-
tative services not mentioned here may contribute to the
various community care systems, so that the effectiveness of
such core services as CMHTs is hard to assess from the size,
composition or case-loads of the teams alone. Nevertheless,
these ﬁgures suggest that community mental health care in
the 6 countries provide somewhat different care on the
ground.
This cost study recorded all contacts of patients with
mental health care services in the respective region, not only
those to services described above to characterize the different
community care concepts.
2.3. Study sample
The original RCT included a total of 507 patients. Their key
workers were randomly assigned to either the intervention or
control condition in order to avoid potential contamination
between intervention groups. Key workers were randomized
with the use of a computer generated random block number
allocation sequence (to ensure an equal balance across sites).
The randomization procedure was completed separately byeach country, per CMHT and was stratiﬁed by professional
background (Community psychiatric nurse, social worker,
support worker etc.) and by the number of patients within
each key worker's case-load that consented to participate.
Overall, the intervention group included 271, the control
group 236 patients. Of these patients, 451 completed the
follow-up. Detailed socio-demographic and morbidity data
are reported elsewhere (Priebe et al., 2007). Due to the
randomised controlled trial design, there were no signiﬁcant
differences in the characteristics of participants in the control
and intervention groups across all sites at baseline. Only
patients with full 12-month coverage of utilisation data were
included into the cost analyses. Additionally to 57 drop-outs
during the follow-up, another 29 patients had to be dropped
from the ﬁnal data set due to incomplete service use
information (Granada 11, Groningen 0, London 7, Lund 3,
Mannheim 6, Zurich 1). The ﬁnal sample for cost analyses
encompassed 422 patients.2.4. Assessments
Clinical assessments as used in the original RCT to
compare clinical outcomes in the control and intervention
groups (Priebe et al., 2007) were seen as potential cost
predictors and included into the cost analyses. These scales
were used:
• the Manchester Short Assessment of Quality of Life
(MANSA) (Priebe et al., 1999), on which patients rate
their satisfaction with 12 life domains on a 7-point scale
from 1 (‘couldn't be worse’) to 7 (‘couldn't be better’). The
mean score of all 12-satisfaction questions was used as a
cost predictor.
• the 8-item Client Satisfaction Questionnaire (CSQ-8)
(Nguyen et al., 1983) assessing clients' general satisfaction
with services.
• the Camberwell Assessment of Need Short Appraisal
Schedule, patient-rated version (CANSAS) (Slade et al.,
1996) which assesses health and social needs across 22
domains, the CANSAS produces two subtotal scores: ‘total
unmet needs’ and ‘total met needs’.
• the Positive and Negative Syndrome Scale (PANSS) (Kay
et al., 1987), a 30-item, 7-point scale from 1 (‘absent’) to 7
(‘extreme’). The PANSS comprises a global score, and three
subscales (positive, negative, and general psychopathology).
• Socio-demographic information and data on mastery,
empowerment, self esteem, drug compliance, and other
domains were also collected at baseline or during follow-up
and used as potential cost predictors.
• Study clients' use of mental health care services was
recorded continuously for twelve months with the Service
Utilization Sheet (SUS), which adapted the service items
and deﬁnitions of the Client Socio-demographic and Service
Receipt Inventory (CSSRI) (Chisholm et al., 2000) and of the
European Service Mapping Schedule (ESMS) (Johnson et al.,
2000).
• Intake of psychotropic medication was assessed cross-
sectionally at baseline and follow-up by recording the brand
name and dosage of each psychotropic drug prescribed for
each patient.
Table 1
Baseline socio-demographic characteristics of patients, means (standard
deviation SD) or proportions (%) (Mansa: Manchester Short Assessment of
Quality of Life, CSQ: Client Satisfaction Questionnaire, Cansas: Camberwell
Assessment of Need Short Appraisal Schedule, PANSS: Positive and Negative
Syndrome Scale).
Mean (SD) or proportion
Patients (n) 422
Mean age (years) 42.3 (11.3)
Gender (% female) 31.8%
Marital status (% single) 70.8%
Unemployed (%) 36.7%







Other non-organic psychotic disorder 16.4%
Length of illness (years) 16.0 (10.1)
Number of hospital admissions 5.2 (7.1)
Quality of life (MANSA) 4.7 (0.8)
Satisfaction with treatment (CSQ) 25.7 (4.2)






Mental health care service utilization across sites (average frequency of
contacts with or days spent in service per patient during the 12-month
follow-up) (CMHC: Community Mental Health Centre).
Granada Groningen London Lund Mannheim Zurich
Sample size 56 94 81 55 66 70
Psychiatric hospital 0.9 18.1 7.8 2.8 13.4 6.2
Emergency/crisis ward 0.1 0 0 0.1 0.1 0.2
General medical wards 0 0 0 0 0 0
Other inpatient services 0 0 0 0.9 0 0
Total hospital days 0.88 18.17 7.78 3.78 13.38 6.27
Outpatient visits 0 0.2 0 42.3 0.4 19.3
Day/night hospital 1.4 0 0 12.1 2.1 1.9
Other outpatient services 0 0.1 0 3.9 0.2 0.6
CMHC 7.4 32.4 24.2 15 5 0.6
Day care 25.9 30 6.1 12.4 56.5 1.6
Sheltered workshop 4.6 3.6 1.7 8.7 53.8 107.1
Sheltered education
service
0.1 0.5 0.7 5.9 4.6 1.2
Other day services 0 0 0 0.1 21.3 14.1
Psychiatrists 0 0 0 0.7 13 3.3
Psychologists 0 0 0 2.1 2.4 1.1
Primary care physicians 3.7 0.3 0 0.4 1.8 0.9
Psychiatric nurses 0 0 0 1.2 1.9 0.1
Social worker 0 0 0 0.2 0.8 0.3
Occupational therapists 0 0 0 1.4 2.1 1.9
District nurses 0 0 0 0.3 2.9 6.9
Home help 0 0.6 1.1 7.2 1 2.4
Other services 0 0 0 0.3 2 8.2
Overnight 24 h staffed 0 0 0.7 13.3 2.8 26.6
Overnight not 24 h
staffed
0 2.9 0 13.0 276.1 135.4
Overnight not staffed 0 0 0 0 0 12.9
Other home 0 0 0 0 0 15.4
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the basis of the medication intake at baseline, assuming that
possible changes in psychotropic drug prescription were
levelled out across the sample and intake patterns at the
group level remained more or less stable over time. Prior to
assigning cost estimates, depot medication was converted
into average doses of mg/day. To avoid double costing, intake
and costs of psychotropic drugs were adjusted for inpatient
stays, during which medication is covered by hospital fees or
rates.
Patient-level cost proﬁles were calculated by weighting all
service contacts during the follow-up with country- or
centre-speciﬁc unit-cost estimates, which were derived
from national data sources. To assign cost estimates for
psychotropic drugs, the lowest national market price for the
respective drugwas used. All cost datawas transformed into €
as a single currency using conversion rates from January 1,
2004. To eliminate price-level differences between countries,
PPP-conversion rates (power purchase parities) were used,
which are routinely calculated by the OECD and provided by
the Statistical Ofﬁce of the European Communities.
2.5. Statistical cost analyses
The total cost of care was adjusted for socio-demographic
and clinical variables to control for inter-site differences of
samples. Due to non-normal errors of the cost variables to be
analysed, standard linear regression for analysing the associa-
tion of costs and socio-demographic or clinical characteristics
were avoided. Instead, cost data were ﬁrst log-transformed
and then analysed by means of linear regression (log-normal
model). For a better clearness of the model-parameters, a
generalised linear model (GLM) was ﬁtted additionally
(Austin et al., 2000), using a gamma distribution and alogarithmic link function. Other than log-normal models,
gamma models allow to process cost data in its original scale.
To analyse data with both of the models can be viewed as an
ad hoc robustness analysis (Wiens,1999). Coefﬁcients derived
from these models may be compared directly and are to be
interpreted as the logarithm of the relative change in cost
associated with a one-unit change in the predictor variable
(or: exponential coefﬁcients provide estimated percentage
increases in costs). Goodness-of-ﬁt was assessed by the
deviance indicating a good ﬁt in case of low values.
Variables for inclusion into the GLM were selected
according to their potential inﬂuence on costs of care during
the follow-up. For detailed results of the variables used as cost
predictors see Table 1 or Priebe et al. (2007). The (regression)
model selection was done in a stepwise procedure. Thus, p-
values of the predictors in the ﬁnal models should be
interpreted in an exploratory manner.
3. Results
Major socio-demographic and disorder related character-
istics of the patients are shown in Table 1. Utilisation ofmental
health care services–which provided the basic data for all cost
calculations–varied considerably across sites (Table 2). After
transforming service utilisation data into cost-of-care data
and adjusting for power purchase parities (PPP), there were
sizeable inter-site differences in the total cost ofmental health
care and inmost of the service types analysed. Average annual
Fig. 1. Average annual total costs of care and service costs across sites in € (ppp-adjusted) (ppp: power purchase parities, CMHC: CommunityMental Health Centre).
74 H.J. Salize et al. / Schizophrenia Research 111 (2009) 70–77costs of mental health care were lowest in Granada (Spain)
and highest in Zurich (Switzerland), where total costs were
more than tenfold higher (Fig. 1).
Numerically, the average costs of psychotropic medication
was much more constant across sites, whereas the average
costs of other services, e.g., hospital or outpatient care, orFig. 2. Percentage of medication costs among tosheltered accommodation, differed remarkably (see Fig. 1).
Drug costs claimed a greater proportion of the mental health
care costs, the smaller the total cost of care of the respective
site was. In Granada, nearly 40% of all costs were accounted
for by antipsychotics or other psychotropic drugs, whereas in
Zurich this proportion was only 4.6% (see Fig. 2).tal mental health care costs across sites.
Table 3
Cost proportions for ﬁrst- and second-generation antipsychotics across sites (100%=average annual medication cost per patient).
Granada Groningen London Lund Mannheim Zurich
% Second generation antipsychotics 49.4% 80.0% 80.5% 64.8% 81.3% 74.5%
% First generation antipsychotics 38.9% 9.7% 8.7% 8.6% 10.9% 5.5%
% Other psychotropic drugs 11.8% 10.3% 10.8% 26.6% 7.8% 20.0%
Total medication cost (100%) 1 181.27 767.98 1 483.70 1 947.08 2 019.46 1 695.40
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psychotics were clearly in favour of the latter andmore or less
constant across sites, with the exception of the Spanish
centre, where the proportion spent on second-generation
antipsychotics was far lower (see Table 3). The proportion of
patients prescribed with second-generation antipsychotics
was 61.1% across all sites. 44.1% of all patients were treated
with ﬁrst-generation antipsychotics and 14% took both drugs.
These proportions differed between centres. Zurich showed
had the largest proportion of patients taking second-genera-
tion antipsychotics (84.3%) and the smallest ﬁrst-generation
group 27.1%. In Granada it was the opposite (42.8% of all
patients taking second-generation- and 62.5% ﬁrst-genera-
tion antipsychotics). The highest share of patients taking both
types of agents was identiﬁed in Lund (23.6%).
To explore this cost variation further, regression models
were ﬁtted separately for two dependent variables:
• total cost of care, and
• medication costs of psychotropic drug intake.
Tables 4 and 5 show the gamma and log-normal regres-
sion models for total cost of care and medication cost
respectively that were calculated due to the skewed distribu-
tion of the cost data (see methods section). The tables show
only predictors from the total set of variables that proved to
be signiﬁcant at p≤0.05 during the model selection proce-
dure in at least one model (boldface). All centre-variables
were tested against the Zurich centre, which was used as a
statistical benchmark due to its high costs.
The exponential coefﬁcients Exp(β) of the gamma or the
log-normal models express the percentage of cost increase
or decrease. Thus, the more than tenfold lower mental
health care costs in Granada compared to Zurich proved toTable 4
Regression model for predictors of total costs of mental health care
(coefﬁcients in boldface are signiﬁcant at p≤0.05) (PANSS: Positive and
Negative Syndrome Scale).
Variable Gamma model Log-normal model
Β Exp(β) β Exp(β)
Centre 1 (Granada)1 −2.3228 0.0980 −2.3974 0.0912
Centre 2 (Groningen)1 −0.9674 0.3801 −1.1207 0.3261
Centre 3 (London)1 −1.4285 0.2397 −1.5398 0.2144
Centre 4 (Lund)1 −0.3952 0.6735 −0.4260 0.6531
Centre 5 (Mannheim)1 −0.6985 0.4973 −0.5728 0.5639
Age −0.0112 0.9888 −0.0099 0.9902
Living situation 0.5376 1.7119 0.5488 1.7312
Main income source −0.8411 0.4312 −0.7366 0.4788
PANSS negative score follow-up 0.0141 1.0142 0.0160 1.0161
Treatment adherence baseline 0.1955 1.2159 0.0568 1.0584
Allocation to experimental group 0.1545 1.1671 0.1373 1.1472
Deviance 282.62 290.09
1Compared against Centre 6 (Zurich, Switzerland).be signiﬁcant. Similarly, both models conﬁrm the cost in
Groningen as being roughly one third of the cost in Zurich, in
London as one quarter, in Lund as two thirds and inMannheim
as approximately half of the costs in Zurich (see Table 4).
Additionally, according to these models, each additional year
of age reduces the total mental health care cost of a patient by
roughly 1%. But being in sheltered accommodation increases
the costs by 71%, whereas a self-earned income or salary cuts
the total cost of care by half.
The inﬂuence of disorder related estimates was much
lower: each additional negative symptom (PANSS) increases
the total care costs by a mere 1.5%, whereas treatment com-
pliance had a higher inﬂuence on costs. However, only the
gamma model conﬁrmed this as a signiﬁcant predictor, while
the log-normal model did not.
The intervention from the original RCT (Priebe et al., 2007)
proved to have no signiﬁcant inﬂuence on the total care cost:
the allocation variable (indicating the experimental or the
control group) showed only a trend towards signiﬁcance in
the gamma model (p≤0.10) and was above the 0.10 level in
the log-normal model. Due to the constituent character of this
variable for the original RCT, it was retained in the model and
shown here, although from a health-economics perspective it
is not statistically signiﬁcant.
The two regression models predicting the medication cost
(Table 5) showed that the inﬂuence of the site-variable is
considerably less, since the costs of psychopharmacologic
drug intake in Lund andMannheim did not differ signiﬁcantly
from those in Zurich in both statistical models. Only Granada
and Groningen showed a drug cost pattern signiﬁcantly less
costly than that of Zurich (shown by both models), whereas
the difference with London was conﬁrmed only by the log-
normal model.
The association between medication costs and drug
compliance at baseline was signiﬁcant. A change from poor
to average, or from average to good compliancewas associatedTable 5
Regression model for predictors of average medication costs (coefﬁcients in
bold are signiﬁcant at p≤0.05).
Variable Gamma model Log-normal model
Β Exp(β) β Exp(β)
Centre 1 (Granada)1 −0.3962 0.6792 −0.6287 0.5333
Centre 2 (Groningen)1 −0.7299 0.4820 −1.4049 0.2454
Centre 3 (London)1 −0.1168 0.8900 −0.4969 0.6084
Centre 4 (Lund)1 0.0792 1.0824 −0.2216 1.8012
Centre 5 (Mannheim)1 0.2133 1.2378 0.0698 1.0723
Age −0.0121 0.9880 −0.0126 0.9875
No. of domains help needed −0.1053 1.1110 −0.1990 1.2202
Drug compliance baseline −0.0798 0.9233 −0.3360 0.7146
Deviance 526.34 937.05
1Compared against Centre 6 (Zurich, Switzerland).
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the gamma model, but not by the log-normal model). Final-
ly, drug costs were associated with needs for care: each
additional domain in which the patient thought professional
help was needed increased costs by 11% to 22%.
4. Discussion
The study conﬁrms the remarkable differences in the total
costs of mental health care for patients with schizophrenia
across European countries. This is the case even though the
participating patients were homogeneous with respect to
diagnosis and other characteristics and all of the relevant
countries agree on community mental health care as a basic
concept for treating patients with schizophrenia. We found
considerably higher inter-site differences than in earlier pan-
European projects (Knapp et al., 2002). However, regional
cost of care did not exceed the ranges found in earlier national
studies (Haro et al., 1998; Salize and Rössler, 1996; Salvador-
Carulla et al., 1999; Stant et al., 2003; Vazquez-Polo et al.,
2005). Compared to earlier multi-center studies, this study
has some methodological advantages which include a long
follow-up and recording period of service utilisation (a full
12 months) and the inclusion of detailed medication costs.
Different price levels across countries were balanced out by
power purchase parities. A weak inﬂuence of different salary
scales for health workers or other factors could not com-
pletely be ruled out, but they are unlikely to account for the
huge variation in total costs.
Service provision and consequently service use differed
remarkably between the included regions. Although all of the
countries practice community care, many reasons may
account for the differences across the psychiatric systems:
different starting points or speciﬁc aims of the national
psychiatric reforms, different organisational characteristics of
overall health care delivery, different ﬁnancing structures,
different mental health care budgets or economic constraints
etc.
Although patients with schizophrenia have a wide range
of needs which may vary individually by amount and type,
our results suggest that the in principle elastic demand curve
of psychiatric care show a clear tendency to follow the
regional availability of services. Thus, the cost of care patterns
reﬂect more or less different national mental health care
concepts and the characteristic range of services to be found
in the participating regions and countries, rather than patient
psychopathology or the actual needs for care. Particularly,
unmet needs did not have a signiﬁcant inﬂuence on total care
costs. If this had been the case, it might have suggested
deﬁcient mental health care in regions with low costs, e.g. in
Granada. However, unmet needs were highest in London, and
not in the Spanish centre where costs were lowest.
Of course, where services are not available, expenses for
them cannot be incurred. However, an absence of speciﬁc
services does not necessarily mean that treatments such
services usually offer are not needed. But when speciﬁc
services for these needs are not available they tend to be
overlooked as a need that requires measures by the profes-
sional care system. For example, among other factors, the
considerable differences in the availability and use of
sheltered accommodation services may be explained bycultural aspects. Families, particularly in southern European
countries such as Spain, are traditionally involved–usually at
their own expenses–in caring for the chronically mentally ill
to a much higher degree than in other European countries. In
Middle Europe or Scandinavia, a more pronounced societal
trend towards weaker family ties may support the imple-
mentation of professional residential services as an essential
part of community mental health care.
As a consequence, total costs of care cannot be seen as an
indicator for the quality or effectiveness of psychiatric care in
a particular region and even less so in cross-border compar-
isons — at least not on the level of analyses that was done
here. For identifying an association between costs and quality
of care much better indicators of the global effectiveness of
mental health care systems are required than are currently
available. Such indicators must cover informal care or any
relevant contribution of families and relatives.
Although the effectiveness of the mental health care
systems or the commensurability of total care costs cannot
ﬁnally be decided on this level, the second set of regression
analyses (on psychopharmacologic costs) in this study does
indicate an association between quality of care and costs. In
these regression models centre effects show far less inﬂuence
on medication costs than they did on the total care costs,
despite the considerable proportion that medication costs
claim of the total mental health care budgets. In the case of
Granada where rehabilitative services or sheltered accom-
modation are scarce, expenditures for medication rose to
nearly 40% of the total expenditure. Medication costs as high
as that may reduce the options for prescribing costly second-
generation antipsychotics, which accounted for the majority
of psychopharmacologic drug costs at all other sites. These
issues are worthy of further exploration.
This relative stability of medication costs compared to the
total cost of care may have several reasons. First of all,
psychopharmacologic drugs represent the backbone of
schizophrenia treatment that requires the lowest infrastruc-
ture of all psychiatric care modalities. So it would probably be
the last of all treatments to be curtailed when cost constraints
limit mental health care spending. Furthermore, a relatively
solid evidence base for the effectiveness of antipsychotic drug
treatment is recognised worldwide supporting the homo-
genisation of drug treatment and the associated costs
internationally. Another explanation may be that drug
prescription is one of the few sectors of mental health care
in which prices are predominantly market driven and far less
state regulated than in most other sectors or services where
costs may vary according to national health policies, health
insurance schemes or public health care spending. Addition-
ally, homogenized price policies of the internationally
operating pharmacological companies may contribute to the
stability of medication costs.
All in all, the huge overall cost differences as found in
this study should be reason enough to stimulate research on
the factors that inﬂuence service provision, costs and their
linkagewith outcomes in greater depth and detail (Washburn,
2008; Möller, 2008; Carpenter and Buchanan, 2008). For this
purpose, it is essential to build an evidence base for the
effectiveness of the service types or treatments for schizo-
phrenic patients in the various care models, and to develop
good indicators for their effectiveness on a system level.
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